American Cancer Society epidemiologists said women who used an estrogen-progesterone hormone replacement therapy combination for less than two years had no increased risk of breast cancer. The U.S. study, which followed 68,369 cancer-free postmenopausal women from 1992 to mid-2005, also showed that use of the combo HRT doubled the risk of lobular breast cancer after three years.

Full Story:

Related Summaries